Inventiva Raises €130m in Debt Financing Led by Claret Capital Partners

Claret Capital Partners committed €43m to a €130m debt financing round for Inventiva that closed on 16 June 2026. The round includes committed tranches plus an uncommitted tranche of up to €20m and forms part of Inventiva’s capital structure optimization announced on 2 June 2026. BlackRock-managed funds and accounts also participated in the financing.

Inventiva is listed on Euronext Paris and NASDAQ under the ticker IVA and is headquartered in Dijon, France. Inventiva is developing lanifibranor, an oral once-daily pan-PPAR agonist being evaluated in the Phase 3 NATiV3 trial. Top-line results from the trial are anticipated in Q4 2026.

Daniel Mallon, Principal at Claret Capital Partners, said the firm is supporting Inventiva at a pivotal stage in its clinical journey. He noted the company’s encouraging Phase 2b results and said the financing provides additional flexibility as Inventiva moves toward key clinical and regulatory milestones in 2026 and 2027.

Joey Mason, Life Sciences Venture Partner at Claret Capital Partners, also commented on the investment.

The financing is the latest in a series of late-stage European biotech investments by Claret Capital as part of its expansion in life sciences.